James Logothetis
Pulmonary Disease · Monroe Twp, NJNPI 1740279124
Payments from drug & device makers
Across 443 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$991
- Amgen$977
- Johnson & Johnson$668
- GSK$641
- AbbVie$363
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,39397%
- Education$2083%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 51 | $1,274 |
| Boehringer Ingelheim | 76 | $991 |
| Amgen | 46 | $977 |
| Johnson & Johnson | 24 | $668 |
| GSK | 55 | $641 |
| AbbVie(2 entities) | 21 | $363 |
| Astellas Pharma US Inc | 14 | $320 |
| E.r. Squibb & Sons, L.L.C. | 12 | $236 |
| Sunovion Pharmaceuticals Inc. | 18 | $229 |
| Novo Nordisk | 23 | $221 |
| Sanofi-aventis U.S. LLC | 12 | $206 |
| Esperion Therapeutics, Inc. | 6 | $155 |
| Lilly USA, LLC | 11 | $150 |
| Gilead | 3 | $130 |
| Pfizer | 10 | $130 |
| Mannkind Corporation | 2 | $129 |
| Amarin Pharma, Inc. | 8 | $105 |
| Mylan Specialty L.p. | 7 | $105 |
| Kowa Pharmaceuticals America, Inc. | 5 | $67 |
| Arbor Pharmaceuticals, Inc. | 5 | $67 |
| Electromed, Inc. | 4 | $43 |
| Shire North American Group Inc | 3 | $42 |
| Regeneron Healthcare Solutions, Inc. | 3 | $42 |
| Avanir Pharmaceuticals, Inc. | 3 | $42 |
| Genentech USA, Inc. | 3 | $40 |
| Philips North America LLC | 3 | $38 |
| Circassia Inc. | 2 | $29 |
| Novartis | 2 | $26 |
| Merck | 2 | $26 |
| Sanofi | 2 | $24 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,601 in reported general payments places this provider in the 75th percentile of 472 pulmonary disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Raloxifene Hcl | 13 | $730 |
| Rosuvastatin Calcium | 16 | $447 |
| Mirtazapine | 13 | $344 |
| Losartan Potassium | 13 | $321 |
| Sertraline Hcl | 13 | $274 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Monroe Twp
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.